Jane S. Ricciuti, RPh, MS

Disclosures

June 03, 2004

In This Article

Respiratory Agents

Advair Diskus
(fluticasone propionate/salmeterol xinafoate) Inhalation

Manufacturer: GlaxoSmithKline

Drug Approval Classification: Supplemental New Drug Application (Approval Date: 4/21/04)

Indication: This supplemental NDA provides for the use of Advair Diskus (fluticasone propionate/salmeterol xinafoate) Inhalation 100/50 mcg in children 4-11 years of age with asthma.

Advair Diskus (Fluticasone propionate/salmeterol xinafoate) Inhalation Letter

Advair Diskus (Fluticasone propionate/salmeterol xinafoate) Inhalation

processing....